Immunosuppression in the treatment of rheumatoid arthritis. Basic principles and available substances.
D000477:Alkylating Agents / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001327:Autoimmune Diseases / Q000503:physiopathology; D001379:Azathioprine / Q000627:therapeutic use; D004912:Erythrocytes / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D008727:Methotrexate / Q000494:pharmacology; D008938:Mitosis / Q000187:drug effects; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology
D000477:Alkylating Agents; D000963:Antimetabolites; D007166:Immunosuppressive Agents; D009588:Nitrogen Mustard Compounds; D001379:Azathioprine; D008727:Methotrexate